Juan Valencia-Ramos

Juan Valencia-Ramos

Auto-generated profile, based on publicly available information

Juan Valencia-Ramos

Pediatric Intensive Care Unit, Department of Pediatrics, Hospital Universitario de Burgos, Burgos, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2018 in Respiratory Care
Verified
Journal Article
Closed access
PDF file
JVJuan Valencia-Ramos
Juan Valencia-Ramos
AMAlicia Mirás
Alicia Mirás
ACAmacia Cilla
Amacia Cilla
COCarlos Ochoa
Carlos Ochoa
JAJuan Arnaez
Juan Arnaez
BACKGROUND: High-flow nasal cannula (HFNC) is increasingly used to provide respiratory support in infants with bronchiolitis. The delivery of aerosol therapy through a jet nebulizer is widely indicated despite its controversial efficacy and poor tolerability. METHODS: This randomized cross-over study aimed to evaluate the comfort and satisfaction of the delivery of aerosol therapy using a nebulization system integrated into HFNC compared with the standard practice of using a jet nebulizer with a face mask. The COMFORT-Behavior (COMFORT-B) scale, a visual analog scale, and a numeric rating scale were used by health professionals and caregivers to assess subjects' levels of comfort and satisfaction. RESULTS: A total of 113 nebulizations (64 via nebulizer with HFNC; 49 via jet nebulizer) were delivered to the 6 subjects included in the study. Use of the nebulizer with HFNC showed increased comfort and satisfaction during nebulization compared to use of the jet nebulizer, as measured by the COMFORT-B scale, the visual analog scale, and the numeric rating scale, with the following median (interquartile range) scores: 10.7 (7–16) versus 14.5 (10–20) ( P = .006), 8.5 (6–10) versus 7 (4–9) ( P = .02), and 3.84 (3.61–4.07) versus 1.83 (1.58–2.08) ( P < .001), respectively. Correlation between the COMFORT-B scale and the visual analog scale using Spearman's rho was −0.757 ( P < .001). The intraclass correlation coefficient for the COMFORT-B scale, visual analog scale, and numeric rating scale, as measured by 2 different nurses, was between 0.75 and 0.87. CONCLUSIONS: The use of a nebulizer incorporated into HFNC therapy results in an increased level of comfort and satisfaction compared to the use of a conventional jet nebulizer in subjects with bronchiolitis who required HFNC therapy. Further studies are needed to determine whether aerosol therapy delivered through HFNC improves the clinical course of this pathology.

28 April 2021 in Viruses
Verified
Journal Article
Open access
PDF file
NMNieves Martínez-López
Nieves Martínez-López
CMCarmen Muñoz-Almagro
Carmen Muñoz-Almagro
CLCristian Launes
Cristian Launes
ANAna Navascués
Ana Navascués
MIManuel Imaz-Pérez
Manuel Imaz-Pérez
MCMaría Cabrerizo
María Cabrerizo
Hand, foot, and mouth disease (HFMD) is a mild illness caused by enteroviruses (EV), although in some Asian countries, large outbreaks have been reported in the last 25 years, with a considerable incidence of neurological complications. This study describes epidemiological and clinical characteristics of EV infections involved in HFMD and other mucocutaneous symptoms from 2006 to 2020 in Spain. EV-positive samples from 368 patients were included. EV species A were identified in 85.1% of those typed EV. Coxsackievirus (CV) A6 was the prevalent serotype (60.9%), followed by EV-A71 (9.9%) and CVA16 (7.7%). Infections affected children (1–6 years old) mainly, and show seasonality with peaks in spring–summer and autumn. Clinical data indicated few cases of atypical HFMD as well as those with neurological complications (associated with the 2016 EV-A71 outbreak). Phylogenetic analysis of CVA6 VP1 sequences showed different sub-clusters circulating from 2010 to present. In conclusion, HFMD or exanthemas case reporting has increased in Spain in recent years, probably associated with an increase in circulation of CVA6, although they did not seem to show greater severity. However, EV surveillance in mucocutaneous manifestations should be improved to identify the emergence of new types or variants causing outbreaks and more severe pathologies.

5 February 2019 in Journal of Clinical Monitoring and Computing
Verified
Journal Article
Closed access
PDF file
JVJuan Valencia-Ramos
Juan Valencia-Ramos
JAJuan Arnaez
Juan Arnaez
SCSara Calvo
Sara Calvo
FGFernando Gomez
Fernando Gomez
IBIsabel Del Blanco
Isabel Del Blanco

26 September 2022 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
PDF file
JVJuan Valencia-Ramos
Juan Valencia-Ramos
CSCarlos Ochoa Sangrador
Carlos Ochoa Sangrador
MGMaría García
María García
POPablo Oyagüez
Pablo Oyagüez
JAJuan Arnaez
Juan Arnaez
Objective To test the hypothesis that greater comfort is achieved using a nebuliser integrated into a high-flow nasal cannula (nebulisation system integrated in high-flow nasal cannula (NHF)) than using a jet nebuliser (JN), and to explore differences in analgesia requirement and the possibility of feeding during nebulisation. Design Randomised cross-over trial. Setting Paediatric intensive care unit. Patients Children aged <24 months diagnosed with bronchiolitis between November 2016 and May 2017. Interventions Nebulisations using NHF and JN. Main outcome measures COMFORT–Behaviour Scale (CBS) and Numerical Rating Comfort Scale (NRSc) were used to measure comfort, and Numerical Rating Satisfaction Scale (NRSs) was used to assess satisfaction before, during and after nebulisation. Other variables included feeding, analgesia, need for being held and respiratory and heart rates. Results Thirty-three children with 233 nebulisations were included in the study. The median age was 3.0 (IQR 2–9) months. Comfort and satisfaction were greater with NHF than with JN. The median staff-recorded CBS, NRSc and NRSs scores for NHF versus JN were 13 (IQR 9–15) vs 17 (IQR 13–23), 8 (IQR 7–0) vs 7 (IQR 4–8), and 4 (IQR 3–4) vs 2 (IQR 2–3), respectively; and caregiver-recorded scores were 12 (IQR 10–15) vs 19 (IQR 13–24), 9 (IQR 7–10) vs 4 (IQR 1–6), and 4 (IQR 3–4) vs 2 (IQR 1–3), respectively (p<0.001). Children who received NHF had lower cardiac and respiratory rates, needed to be held less often during therapy and required less analgesia (p<0.001). Conclusion Nebulisation through NHF appears to be a better alternative to JN in terms of comfort and satisfaction as well as making feeding possible during nebulisation.

7 February 2019 in Experimental Lung Research
Verified
Journal Article
Closed access
JVJuan Valencia-Ramos
Juan Valencia-Ramos
JAJuan Arnaez
Juan Arnaez
JBJosé Manuel Benito
José Manuel Benito
AMAlicia Mirás
Alicia Mirás
COCarlos Ochoa
Carlos Ochoa
SBSagrario Beltrán
Sagrario Beltrán
Aim of Study: The use of a nebulizer paired with high-flow nasal cannulas (HFNC) has been proposed for drug delivery in bronchiolitis. Particle size nebulized is a relevant factor determining the efficacy of the nebulization. We replicated in vitro the theoretical parameters most widely used in bronchiolitis and we compared the size of the droplet nebulized with a standard nebulizer and a nebulizer integrated into HFNC. Materials and Methods: We used laser diffraction to analyze the particle size nebulized (volume median diameter Dv50). The standard system was a jet nebulizer connected to a facemask with a flow rate of 8 L/min (JN). Three designs were used as nebulizers integrated into HFNC: a vibrating mesh nebulizer set 1) before (HFNC-BH) and 2) after (HFNC-AH) the humidifier, and 3) a jet nebulizer connected before the nasal cannula (HFNC-BNC). HFNC was used with neonatal (3–8 L/min) and infant cannulas (8–15 L/min). Results: Droplet size was similar among the three drugs studied. A lower particle size was obtained when using the nebulization system integrated into HFNC compared to the standard nebulizer, regardless of the flow rate and the nasal cannula used when the position of the nebulizer was before the nasal cannula (p < 0.05): 6.89 µm (JN), 2.49 µm (HFNC-BNC 3 L/min), 2.59 µm (HFNC-BNC 5 L/min), 2.44 µm (HFNC-BNC 8 L/min), 3.22 µm (HFNC-BNC 10 L/min), 3.23 µm (HFNC-BNC 13 L/min), 3.16 µm (HFNC-BNC 15 L/min). The particle size was lower in HFNC-BF compared to the HFNC-AH using neonatal nasal cannula (3–8 L/min) (p < 0.05). Conclusion: The use of a nebulizer integrated with HFNC has shown promising results in an experimental scenario of bronchiolitis. The particle size achieved with the nebulizer placed before the humidifier is equivalent to the one obtained via conventional nebulization, and it is even smaller when the integrated nebulizer is placed before the nasal cannulas.

4 April 2024 in Research Square
Verified
Preprint
Open access
PDF file
LBLorena Bermúdez Barrezueta
Lorena Bermúdez Barrezueta
JMJuan Mayordomo-Colunga
Juan Mayordomo-Colunga
MMMaría Miñambres
María Miñambres
SRSusana Reyes
Susana Reyes
JRJuan Valencia Ramos
Juan Valencia Ramos
MPMartí Pons-Òdena
Martí Pons-Òdena
Background: The objective of this study was to analyze the effects of sedation administration on clinical parameters, comfort status, intubation requirements, and the pediatric intensive care unit (PICU) length of stay (LOS) in children with acute respiratory failure (ARF) receiving noninvasive ventilation (NIV). Methods: Thirteen PICUs in Spain participated in a prospective, multicenter, observational trial from January to December 2021. Children with ARF under the age of five who were receiving NIV were included. Clinical information and comfort levelswere documented at the time of NIV initiation, as well as at 3, 6, 12, 24, and 48 hours. The COMFORT-behavior (COMFORT-B) scale was used to assess the patients’ level of comfort. NIV failure was considered to be a requirement forendotracheal intubation. Results: A total of 457 patients were included, with a median age of 3.3 months (IQR 1.3-16.1). Two hundred and thirteen children (46.6%) received sedation (sedation group); these patients had a higher heart rate, higher COMFORT-B score, and lower S/F ratio than did those who did not receive sedation (non-sedationgroup). A significantly greater improvement in the COMFORT-B score at 3, 6, 12, and 24 hours, heart rate at 6 and 12 hours, and S/F ratio at 6 hours was observed in the sedation group. Overall, the NIV success rate was 95.6% -intubation was required in 6.1% of the sedation group and in 2.9% of the other group (p =0.092). Multivariate analysis revealed that the PRISM III score at NIV initiation (OR 1.408; 95% CI 1.230–1.611) and respiratory rate at 3 hours (OR 1.043; 95% CI 1.009–1.079) were found to be independent predictors of NIV failure. The PICU LOS was correlated with weight, PRISM III score, respiratory rate at 12 hours, SpO2 at 3 hours, FiO2 at 12 hours, NIV failure and NIV duration. Sedation use was not found to be independently related to NIV failure or to the PICU LOS. Conclusions: Sedation use may be useful in children with ARF treated with NIV, as it seems to improve clinical parameters and comfort status but may not increase the NIV failure rate or PICU LOS, even though sedated children were more severe at technique initiation in the present sample.